The mean expression of LAG-3 in active MM patients was significantly higher compared to the control group (27.69 ± 3.27% vs. 2.441 ± 0.51%, mean ± SEM, p < 0.0001, respectively), and was also higher compared to premalignant conditions (16.58 ± 2.85%, mean ± SEM, p = 0.025), as shown in Figure 1A. This evidence concerns the gene LAG3 and Miyoshi myopathy.